STAT3 inhibition mitigates experimental autoimmune gastritis by restoring Th17/Treg immune balance.

IF 3.3 4区 医学 Q3 IMMUNOLOGY
Aiqing Zhang, Lingyun Niu, Yahui Ni, Wenjuan Liu, Xiaoxue Gao, Le Chang, Ping Cao
{"title":"STAT3 inhibition mitigates experimental autoimmune gastritis by restoring Th17/Treg immune balance.","authors":"Aiqing Zhang, Lingyun Niu, Yahui Ni, Wenjuan Liu, Xiaoxue Gao, Le Chang, Ping Cao","doi":"10.1007/s12026-025-09643-4","DOIUrl":null,"url":null,"abstract":"<p><p>This study investigates the role of STAT3 in autoimmune gastritis (AIG) pathogenesis and evaluates the therapeutic potential of STA-21, a STAT3 inhibitor. We utilized these models. (1) AIG model establishment using TxA23 mice, (2) high-dose tamoxifen (HDT) treatment to induce gastric atrophy and spasmolytic polypeptide-expressing metaplasia (SPEM), and (3) STA-21 administration to assess STAT3 inhibition. Mice were divided into TxA23 early-stage (2-4 months), advanced-stage (6-12 months), STAT3 knockout (TxA23 × STAT3⁻/⁻), and STA-21-treated (10 mg/kg/day for 1 month) groups. BALB/c mice were included for HDT experiments. HDT (80 mg/kg/day) and STA-21 (10 mg/kg/day) were administered by oral gavage for 1 month. Gastric tissues were analyzed to assess inflammation, immune cell populations, and cytokine expression. H&E staining evaluated histological changes, while immunohistochemistry assessed Ki67 (proliferation marker) and SPEM markers (TFF2, MUC6, CD44v9). Flow cytometry quantified CD4⁺IL-17⁺ (Th17) and CD4⁺FOXP3⁺ (Treg) cells, while qPCR and ELISA measured pro-inflammatory (IL-17, IL-21, IL-23R, RORγt) and anti-inflammatory markers (IL-10, FOXP3). STAT3 and p-STAT3 were significantly upregulated in TxA23 AIG mice, correlating with inflammation, atrophy, and mucus hyperplasia. STAT3⁻/⁻ mice exhibited reduced inflammation, preserved parietal cells, and suppressed epithelial hyperproliferation, alongside decreased SPEM markers (TFF2, MUC6, CD44v9). STA-21 treatment alleviated gastric atrophy, reduced inflammatory infiltration, suppressed Th17 differentiation, and enhanced Treg function, reversing the Th17/Treg imbalance. STAT3 inhibition alleviated autoimmune gastritis by restoring Th17/Treg balance, reducing inflammation, and potentially limiting early metaplastic changes, although long-term progression was not evaluated.</p>","PeriodicalId":13389,"journal":{"name":"Immunologic Research","volume":"73 1","pages":"90"},"PeriodicalIF":3.3000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunologic Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12026-025-09643-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study investigates the role of STAT3 in autoimmune gastritis (AIG) pathogenesis and evaluates the therapeutic potential of STA-21, a STAT3 inhibitor. We utilized these models. (1) AIG model establishment using TxA23 mice, (2) high-dose tamoxifen (HDT) treatment to induce gastric atrophy and spasmolytic polypeptide-expressing metaplasia (SPEM), and (3) STA-21 administration to assess STAT3 inhibition. Mice were divided into TxA23 early-stage (2-4 months), advanced-stage (6-12 months), STAT3 knockout (TxA23 × STAT3⁻/⁻), and STA-21-treated (10 mg/kg/day for 1 month) groups. BALB/c mice were included for HDT experiments. HDT (80 mg/kg/day) and STA-21 (10 mg/kg/day) were administered by oral gavage for 1 month. Gastric tissues were analyzed to assess inflammation, immune cell populations, and cytokine expression. H&E staining evaluated histological changes, while immunohistochemistry assessed Ki67 (proliferation marker) and SPEM markers (TFF2, MUC6, CD44v9). Flow cytometry quantified CD4⁺IL-17⁺ (Th17) and CD4⁺FOXP3⁺ (Treg) cells, while qPCR and ELISA measured pro-inflammatory (IL-17, IL-21, IL-23R, RORγt) and anti-inflammatory markers (IL-10, FOXP3). STAT3 and p-STAT3 were significantly upregulated in TxA23 AIG mice, correlating with inflammation, atrophy, and mucus hyperplasia. STAT3⁻/⁻ mice exhibited reduced inflammation, preserved parietal cells, and suppressed epithelial hyperproliferation, alongside decreased SPEM markers (TFF2, MUC6, CD44v9). STA-21 treatment alleviated gastric atrophy, reduced inflammatory infiltration, suppressed Th17 differentiation, and enhanced Treg function, reversing the Th17/Treg imbalance. STAT3 inhibition alleviated autoimmune gastritis by restoring Th17/Treg balance, reducing inflammation, and potentially limiting early metaplastic changes, although long-term progression was not evaluated.

STAT3抑制通过恢复Th17/Treg免疫平衡减轻实验性自身免疫性胃炎。
本研究探讨STAT3在自身免疫性胃炎(AIG)发病机制中的作用,并评估STAT3抑制剂STA-21的治疗潜力。我们利用了这些模型。(1)用TxA23小鼠建立AIG模型;(2)大剂量他莫昔芬(HDT)诱导胃萎缩和表达痉挛多肽的化生(SPEM);(3)给药STA-21评估STAT3的抑制作用。小鼠被分为TxA23早期(2-4个月)、晚期(6-12个月)、STAT3敲除(TxA23 × STAT3毒血症)和sta -21治疗组(10 mg/kg/天,持续1个月)。采用BALB/c小鼠进行HDT实验。HDT (80 mg/kg/d)和STA-21 (10 mg/kg/d)灌胃1个月。分析胃组织以评估炎症、免疫细胞群和细胞因子表达。H&E染色评估组织学变化,免疫组织化学评估Ki67(增殖标志物)和SPEM标志物(TFF2, MUC6, CD44v9)。流式细胞术量化CD4 + IL-17 + (Th17)和CD4 + FOXP3 + (Treg)细胞,qPCR和ELISA检测促炎标志物(IL-17、IL-21、IL-23R、RORγt)和抗炎标志物(IL-10、FOXP3)。STAT3和p-STAT3在TxA23 AIG小鼠中显著上调,与炎症、萎缩和粘液增生相关。STAT3毒血症表现为炎症减轻,保存了壁细胞,抑制了上皮细胞的过度增殖,同时减少了SPEM标记物(TFF2, MUC6, CD44v9)。STA-21治疗可缓解胃萎缩,减少炎症浸润,抑制Th17分化,增强Treg功能,逆转Th17/Treg失衡。STAT3抑制通过恢复Th17/Treg平衡、减少炎症和潜在地限制早期化生改变来减轻自身免疫性胃炎,尽管长期进展尚未评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Immunologic Research
Immunologic Research 医学-免疫学
CiteScore
6.90
自引率
0.00%
发文量
83
审稿时长
6-12 weeks
期刊介绍: IMMUNOLOGIC RESEARCH represents a unique medium for the presentation, interpretation, and clarification of complex scientific data. Information is presented in the form of interpretive synthesis reviews, original research articles, symposia, editorials, and theoretical essays. The scope of coverage extends to cellular immunology, immunogenetics, molecular and structural immunology, immunoregulation and autoimmunity, immunopathology, tumor immunology, host defense and microbial immunity, including viral immunology, immunohematology, mucosal immunity, complement, transplantation immunology, clinical immunology, neuroimmunology, immunoendocrinology, immunotoxicology, translational immunology, and history of immunology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信